US3755581036 - Common Stock
77.09 -0.56 (-0.72%)
After market: 77.2 +0.11 (+0.14%)
GILEAD SCIENCES INC
NASDAQ:GILD (5/26/2023, 7:27:38 PM)
After market: 77.2 +0.11 (+0.14%)77.09
-0.56 (-0.72%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The firm offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The firm's other products include AmBisome and Letairis. The company also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA 94404
P: 16505743000.0
CEO: Daniel P. O'Day
Employees: 17000
Website: https://www.gilead.com/
/PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with...
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END
Roche tested its treatment in patients with liver cancer and found "meaningful" results.
A committee of the European Medicines Agency ((EMA)) recommended the expanded use of Gilead Sciences (GILD) COVID drug Veklury (remdesivir). Read more here
Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: